Login
MAXCYTE, INC. logo

MAXCYTE, INC.

maxcyte.com

What Do They Do?

Sells cell-engineering instruments, single-use processing assemblies and consumables to cell therapy developers, biopharmaceutical companies and research institutions.

How Do They Make Money?

Customers buy instruments, processing assemblies, consumables and assay services; instrument license fees cover the license term. SPL customers may also owe payments when programs reach development milestones and sales-based payments on commercialized therapies.

revenue
SegmentShareRevenue
Product sales
Sold outright

57%
FY2022: 63%
Licenses
Recurring

37%
Assay and other service revenue
Sold outright
6.0%

Who Are Their Customers?

Cell therapy developers, biopharmaceutical and biotechnology companies, and academic and government research institutions use the platform. MaxCyte sells instruments to research users and licenses them to academic and commercial customers for research or clinical work.

Customers above 10% of revenue, FY2025
of revenue from one customer
FY2024: 23% from one customer

Do Revenues Turn Into Profits?

No. It lost $44.6M in FY2025.

Operating income, FY2025
−157% of revenue
▼ −1% (Loss) vs FY2024 (−$51.2M, −133%)
Net income, FY2025
−135% of revenue
▼ −9% (Loss) vs FY2024 (−$41.1M, −106%)
Free cash flow, FY2025
−110% of revenue
▼ −24% (Loss) vs FY2024 (−$29.3M, −76%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +49%
vs $6.8M in Q3 FY2025
Net income
▲ +62% (Loss)
vs −$12.4M in Q3 FY2025
Product sales share of revenue vs 57.9% in Q3 FY2025
  • Oct 14, 2026 Raises full-year revenue guidance The new full-year outlook is approximately $34 million, versus prior guidance of $30 million to $32 million.
  • Aug 12, 2026 Signs a multi-platform technology license partnership with Genentech The company described it as its first enterprise-level agreement of this kind with a large pharmaceutical company.
  • Mar 23, 2026 Appoints Parmeet Ahuja as chief financial officer He succeeds Douglas Swirsky, who is transitioning from the role.

Flat. Revenue was $33M in FY2025, about the same as the $33.9M of FY2021.

Added a discovery instrument The latest report describes DTx for discovery among the ExPERT instruments, while the older report listed the ATx, STx, GTx and VLx.

Expanded gene-editing assessment services The latest report describes SeQure's gene-editing assessment services alongside MaxCyte's electroporation platform; the acquisition expanded services for cell and gene therapy developers.

Revenue over time
Product sales Licenses Assay and other service revenue Other
$50M$25M$0

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support